Liquid chromatographic method was developed and validated for quantitative determination of quinine in polymeric nanoparticles. The method was performed using a Waters RP-18 column using a mobile phase consisting of acetonitrile:water:triethylamine (60:40:0.01 v/v/v, and pH aqueous phase adjusted to 3.0 with phosphoric acid). The flow rate was 1.0 mL min -1 and the detection was achieved with a UV-PDA set at 232 nm. The response was linear over a range of 12.0 to 24.0 µg.mL -1 (r = 0.9995). The relative standard deviation values for intra-day and inter-day precision studies were less than 2% and the accuracy was 98.8% to Nc1 and 97.3% to Nc2.
INTRODUCTION
Quinine (figure 1) is an alkaloid extracted from the bark of the cinchona and is the antimalarial drug that has been in use for over 400 years (Achan et al., 2012 ). Generally it is used in monotherapy (Meshnick and Dobson, 2001) , however, the adverse effects in high doses and the increasing parasite resistance to cinchona alkaloids have made necessary a combination with a second drug (WHO, 2012) . This drug is used as a second line treatment of uncomplicated malaria and as preferential line treatment of malaria in (Taylor and White, 2004 ) the first trimester of pregnancy (WHO, 2010) . It is rapidly absorbed orally and has a good tissue distribution, but is hardly accumulated, since it is rapidly metabolized and excreted (Salako and Sowunmi, 1992) . The great advantage of quinine as an antimalarial is its adequate solubility for intravenous formulations and is of great importance in the treatment of patients who do not tolerate oral medication (Wiesner et al., 2003) . However, the required high doses administration by the intravenous route can cause severe cardiac arrhythmia and even fatal hypotension (Vale et al., 2005) . Besides that, quinine is photo unstable (Christensen et al., 2000) . From this, an improvement of the quinine therapeutic index could play an important role in the treatment of drug resistant malaria. The drug carrier system has been extensively studied as vectors that allow control of drug delivery to specific sites in the treatment of many diseases (Duncan and Gaspar, 2011) . Among these, we highlight the carrier nanoparticulate systems which are defined as colloidal particles, or pharmacologically active with the ability to carry therapeutic agents, which is in the nanometer range of 10 to 1000 nm (1µm) (Nagavarma et al., 2012 , Caban et al., 2014 . Quinine-loaded nanocapsules have been developed and shown to increase drug efficacy in rats infected with Plasmodium berghei (Haas et al., 2009) . The essential characterization of drugs-loaded nanoparticles is particle size, zeta potential, polydispersibility, pH, entrapment efficiency and drug loading (Hall et al., 2007) . For the last two, the quantification techniques play an important role. Quantification of quinine is usually by liquid chromatography system with fluorescence detection (Haas et al., 2009 , Mirghani et al., 1998 .
The MS detection is also used because of the high sensitivity and specificity of this technique for identification and quantification of drugs at low concentrations in raw materials, pharmaceutical formulations, and biological matrices (Brum et al., 2011) . However, UV detection is often preferred, because it is cheaper and more easily available. No analytical techniques are described for dosing quinine in pharmaceutical formulations using high performance liquid chromatography (HPLC) and UV detection, which is sensitive to compounds that absorb light and are easy to operate as well as it possess a good stability and is more commonly used in HPLC analysis (Argenton, 2010) . Thus, the goal of this study was to develop and validate a method for the determination of this quinine in nanoparticulate systems dosage forms using diode array UV detector as a new methodology, according to the current International Conference on Harmonization (ICH) guidelines (ICH, 1996 , ICH, 2003 , ICH, 2005 , thereby contributing to the development of new alternatives techniques for the quality control of different pharmaceutical formulations based on cinchona alkaloids.
MATERIAL AND METHODS

Chemical and Reagents
The Quinine (QN) (90% purity) was obtained from Sigma Aldrich Ltd (São Paulo, Brazil). Acetonitrile and methanol solvents were obtained from Tedia (Fairfield,USA). Purified water was prepared using a Milli-Q Plus (Millipore, Bedford, USA). All other reagents and chemicals used were of pharmaceutical or special analytical grade.
Instrumentations
The analysis were performed on a Shimadzu LC system (Kyoto, Japan), which consisted of a LC-20AT pump, a SPD-M20A photodiode array (PDA) detector, a CBM-20A system controller, a DGU-20A3 degasser and a SIL-20A autosampler. Data were acquired and processed using LC Solution software (Release 1.22 SP1). Chromatographic separation was achieved on a 5 μm Waters RP-18 column (4.6 mm x 300 mm), with a guard column (4 x 3 mm i.d.) packed with the same material. Photodegradation was carried out in a photostability UV chamber (1.0 x 0.17 x 0.17 m) with mirrors and equipped with an UV-A lamp (Orion, 352 nm, 30 W, 130 V) and UV cuvettes (BRAND®), used as a container for samples.
Chromatographic Conditions
The chromatographic analysis was performed at the standard temperature (23 ± 1 ºC), using a mobile phase composed of acetonitrile:water:triethylamine (60:40:0.01 v/v/v). The aqueous phase was adjusted to pH 3.0 with phosphoric acid). After preparation, the mobile phase was filtered through a 0.45 µm membrane filter (Millipore, Bedford, USA) and degassed using an ultrasonic bath for 20 min. The flow rate was 1.0 mL min -1 and quinine was detected at 232 nm after injection of 20 µL.
Preparation of Quinine-Loaded Nanocapsules
Two different nanocapsules were prepared by interfacial deposition of PCL (Fessi et al., 1988; Haas et al., 2009) , denominated formulation 1 (Nc 1 QN) and formulation 2 (Nc 2 QN). The organic phase Nc 1 QN was composed of poly (ɛ-caprolactone) (PCL) (0.1 g), Lipoid S45 ® surfactant (0.078 g), quinine (2 mg.mL
), caprylic/capric triglyceride (330 µL), prepared in acetone (27 mL) in temperature of 45 ± 1 ºC, which was added to the aqueous phase composed of distilled water (53 mL), polysorbate 80 (Tween 80 ® ) (0.078 g) and polietilenoglicol (PEG 4000) (0.07g). In the organic phase Nc 2 QN, the PCL polymer was replaced with the positively charged polymer Eudragit RS100 ® (0.1 g), the surfactant Lipoid S45 ® was replaced by Span 60 ® (0.078 g). The aqueous phase was composed of distilled water (53 mL) and Tween 80® (0.078 g). Nanocapsules without QN were also prepared and designed blank nanocapsules (NC 1 BR or NC 2 BR).
Preparation of Standard Solution and Samples
Stock solution of QN (1000 μg.mL -1 ) was prepared by dissolving accurately weighed 10 mg in acetonitrile using 10 mL volumetric flask. Standard solution was prepared by dilution of the diluted stock solution with mobile phase to obtain solutions in a final concentration of 20 μg mL -1
. To prepare the sample solutions, 0.1 mL of nanoparticulate systems (2 mg.mL -1 of QN) was transferred into a 10 mL volumetric flask, with 10 mL of acetonitrile, obtaining the final concentration of 20 µg.mL -1
. This flask was kept in an ultrasonic bath for 30 min. The solutions were filtered through a 0.45 µm membrane filter before injection.
VALIDATION OF THE METHOD
The developed chromatographic method was validated using quinine-loaded nanocapsules NC 1 QN and NC 2 QN with the label claim of 2 mg.mL -1 , by determination of specificity, linearity, precision, accuracy, robustness and system suitability, following ICH guidelines.
Linearity and sensitivity
Linearity was evaluated by constructing three calibration curves, each one with 7 concentration levels of QN (12, 13.5, 15, 16.5, 18, 21, ) on three different days. The results were tested by ANOVA and linear regression analysis was used to obtain the linear equation and correlation coefficient. The limits of detection (LOD) and quantitation (LOQ) were calculated using the direct calibration line. The LOQ was calculated by multiplying the factor 10 for the intercept and dividing the value obtained by the slope of the average. The same procedure was used for the calculation of LOD, however the factor used was 3.3, according to the guidelines (ICH, 1996 , ICH, 2003 , ICH, 2005 .
Precision
The intra-day precision was analyzed through the preparation of 6 samples of nanocapsules (Nc 1 QN e Nc 2 QN) containing 20 μg.mL -1 of QN, on the same day (n = 6). Inter-day precision was tested by repeating the same procedure on 3 different days (n = 6/day) and comparing the results for the different days. The precision data were expressed as relative standard deviation percentage (RSD%).
Accuracy
The accuracy of the method was evaluated by adding a known amount of QN at three concentrations (16, 20, 24 µg.mL ). Each solution was prepared in triplicate and the concentrations and recoveries were calculated against the added concentration.
Robustness
Robustness of the proposed method was examined by evaluating the influence of small alterations of the most important procedure variables such as the ratio of mobile phase ACN: MeOH: water pH 3. 0 (40:40:20 and 50:30:20) , flow change (0.8 and 1.2ml / min) and pH (2.8 and 3.2). Analyses of nanocapsules containing 20 μg.mL -1 QN were carried as the same form described above (item 2.5), in triplicate. Only one parameter in the experiments was changed at a time and the effects were studied based on RSD (%) values obtained among the parameters analyzed. In order to evaluate the robustness the values obtained after different tests were compared in relation to Rt (retention time), T (tailing factor ≤ 2.0), k (retention factor ≥ 2.0) and N (theoretical plate number ≥ 2000) according to the limits established by FDA (FDA, 1994) .
Specificity
The specificity was performed by observing interferences from quinine-loaded nanocapsules excipients. The chromatograms of excipient placebo solution (without drug) and antimalarial solutions were compared to verify the probable interference of the excipients on the drug quantitation.
Nanocapsules applicability
Photodegradation was induced by exposing the samples to UV-A radiation (352 nm) for 8 h. The samples of free QN, Nc 1 QN and Nc 2 QN were added in cuvettes (2 mL) inside the chamber (n = 3). In specific times, an aliquot of each sample was withdraw for HPLC-PDA analysis. Samples were analyzed in comparison to the control sample (free QN) which was also subjected to degradation conditions. After each time degradation, all samples were submitted to dilution in acetonitrile to yield a final concentration of 20 µg.mL -1 and filtration in a 0.45 µm membrane filter, before injection.
RESULTS AND DISCUSSION
The development and validation of the analytical method quinine-loaded nanocapsules allows a simple and rapid quantitative estimate. This novel method quantifies QN in different nanoparticle systems and uses photodiode array UV detection with optimal chromatographic conditions.
The nanocapsules have been characterized according to the diameter, pH and zeta potential. Both formulations have a diameter in the range between 150 and 200 nm and polydispersity -below 2 confirming the homogeneity of particle size distribution.
The pH of the formulations showed between 7 and 8 for both formulations because of the high basicity of quinine. The zeta potential indicates that the electrical potential of the particle surface was around -25 and +15 mV for NC 1 QN and NC 2 QN, respectively.
This difference is because of the cationic polymer Eudragit RS100 ® , giving positive charge to NC2QN and the polymer (PCL) and the surfactant (Lipoid S45 ® ), responsible for the negative charge of NC 1 QN (Schaffazick et al., 2002 , Mosqueira et al., 2001 . These results are in agreement with Haas and co-workers (Haas et al., 2009 ). The best chromatographic condition was achieved using a mobile phase consisting of acetonitrile and water 0.01% triethylamine (pH adjusted to 3.0 with phosphoric acid) (60:40, v/v), with a flow rate of 1.0 mL min -1 and total run time of 08 minutes. QN produced a sharp and symmetric peak when chromatographed with these conditions. A typical chromatogram of QN standard, NC 1 QN and NC 2 QN obtained by the proposed method is shown in Figure 2A , 2B and 2C, respectively. PDA detector enables the analysis of a drug at different wavelengths in a single analysis, as well as to verify peak purity during analysis, so we chose to use the wavelengths of maximum absorption for QN (232 nm) in order to obtain the maximum area for each peak. The retention time for quinine was 06 minutes.
QN linearity was evaluated in the concentration range of 12-24 µg.mL -1 . The calibration curves constructed for QN were found to be linear and the equation obtained was y = 103.540,2232x + 68.439,8428, where y is the peak area ratio of QN and x is the concentration of QN in µg.mL , respectively, indicating suitable sensitivity of the method.
The repeatability of the method was determinate by the RSD for six determinations of QN performed on the same day and under the same experimental conditions (intra-day). The inter-day precision was assessed by analyzing six samples on three different days. These results are given in Table I . The low RSD (%) was obtained for the intra-day (< 1.0 %) and inter-day precision (0.875% for Nc 1 QN and 0.629% for Nc 2 QN). The Nc 1 QN showed a slightly label claim concentration higher than Nc 2 QN, but different particulate systems had a lower RSD% in inter-day precision and in intra-day accuracy, confirming good precision of the quinine-loaded nanocapsules method. The accuracy was calculated as the percentage of recovery by the assay of adding a . known amount of quinine at three concentrations to blank nanocapsules. The accuracy of the method ranged from 98 to 99.6 % to Nc 1 and from 97 to 97.8% to Nc 2 , with RSD lower than 2.0%. The recovery of almost all the drug in the sample in three different (high, medium and low) concentrations with a low RSD % indicates that the assay is accurate (Table II) .
Robustness of the proposed analytical method was evaluated by changes in the chromatographic conditions as flow rate, mobile phase composition and pH. The samples of Nc 1 QN and Nc 2 QN were performed in triplicate and injected for each of the changes and system suitability parameters evaluated. The values of the selected variables evaluated in the robustness assessment are shown in Table III . All conditions evaluated resulted in small changes in the retention time, tailing factor and theoretical plate number in comparison with the proposed analytical conditions. The results were satisfactory in accordance with the literature (ICH, 1996; ICH, 2003; ICH, 2005) . No significant differences related to the quantification of quinine (RSD < 2.0%) and none of these alterations caused a significant effect on the determination of this drug in nanocapsules, indicating the robustness of the method. The specificity of the method for QN was established through determination of the purity peak of the analyte in the working standard solution using a PDA detector.
No interference from formulation excipients was found in the same retention time of the drug, showing that the peaks were free from any co-eluting peak, demonstrating that the proposed method is specific for the analysis of QN. In photodegradation studies after 8 hours of exposure to UV-A light, quinine standard had a degradation of 27.11 ± 0.218%. However, the nanocapsules samples had a degradation of 11.92 ± 0.508% and 13.34 ± 0.628% for Nc 1 QN and Nc 2 QN, respectively. Even after 8 hours of exposure to UV-light there was no formation of degradation products for both the standard ( Figure  3D ) and the QN nanocapsules ( Figure 3E and 3F ), but only a decrease in the content of QN.
Through these results, it is clear that the nanoencapsulation of QN protects the drug from degradation by exposure to UV-A light. This indicates that the tested nanocapsules are alternative systems that protect sensitive drugs to light degradation. In the photodegradation was observed protection of quinine by the nanoparticles after 8 hours of exposure to UV-A radiation, which did not occur with the quinine standard, which had twice the degradation compared to nanoparticulate systems. Through these results, it is clear that the nanoencapsulation of QN protects the drug from degradation by exposure to UV-A light. This indicates that the tested nanocapsules are alternative systems that protect sensitive drugs to light degradation. 
